F060 Vulvar Disease: What Do You Know? An Overview
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Nearly one in six women experience undiagnosed and untreated vulvovaginal discomfort during their lives. This forum will focus on management pearls for treating patients with vulvar dermatoses. Test your knowledge as speakers review cases highlighting challenging clinical scenarios.
This activity has been approved by the American Board of Dermatology (ABD) for up to 20 Continuing Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org
LEARNING OBJECTIVES
Develop a practical, clinical approach to the evaluation of vulvar disorders
Assess, diagnose, and manage both common and more challenging vulvar dermatoses
Recognize the broad differential diagnosis of vulvar conditions using interactive clinicopathologic correlations
SCHEDULE
5:00 PM
Introduction and Welcome
Melissa Muszynski Mauskar, MD, FAAD
5:15 PM
Interactive case presentations
Audrey Kay Rutherford, MD, FAAD
5:30 PM
Interactive case presentations
Erin Foster, MD, FAAD
5:45 PM
Q/A
Erin Foster, MD, FAAD, Audrey Kay Rutherford, MD, FAAD
5:50 PM
Interactive case presentations
Olushola Akinshemoyin Vaughn, MD, FAAD
6:05 PM
Interactive case presentations
Alicia J Little, MD, PhD, FAAD
6:20 PM
Q/A
Olushola Akinshemoyin Vaughn, MD, FAAD, Alicia J Little, MD, PhD, FAAD
6:25 PM
Rapid Fire - Stump the Experts
6:50 PM
Q/A
SPEAKERS
Olushola Akinshemoyin Vaughn, MD, FAAD
Erin Foster, MD, FAAD
Alicia J Little, MD, PhD, FAAD
Melissa Muszynski Mauskar, MD, FAAD
Audrey Kay Rutherford, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Olushola Akinshemoyin Vaughn, MD, FAAD
No financial relationships exist with ineligible companies.
Erin Foster, MD, FAAD
Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); National Eczema Association – Consultant (1099 relationship)(No Compensation Received);
Alicia J Little, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Melissa Muszynski Mauskar, MD, FAAD
Incyte Corporation – Investigator(Grants/Research Funding); Nuvig Therapeutics – Advisory Board(Honoraria);
Audrey Kay Rutherford, MD, FAAD
No financial relationships exist with ineligible companies.